Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Natco Pharma Ltd. Share Price
Day's Range
Day's Range
Low
₹920.10
High
₹933.95
Price Summary
| Previous Close | ₹925.05 |
|---|---|
| Day's Range | ₹920.10 - ₹933.95 |
| Open | ₹927.10 |
| 52 Week Range | ₹789.00 - ₹1,226.80 |
| Volume | 1,51,767 |
| Market Cap | ₹0.02 |
| Previous Close | ₹924.65 |
|---|---|
| Day's Range | ₹920.40 - ₹934.85 |
| Open | ₹932.65 |
| 52 Week Range | ₹789.30 - ₹1,226.10 |
| Volume | 32,485 |
| Market Cap | ₹0.02 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 1,403.90 |
|---|---|
| Market Cap (₹ in Mn) | 0.02 |
| Dividend Yield(%) | 0.54 |
| Price/Earning (TTM) | 11.68 |
| TTM EPS (₹) | 79.20 |
| P/E Ratio | 7.57 |
| Book Value(₹) | 1.80 |
| PAT Margin (%) | 39.54 |
| Face Value (₹) | 2.00 |
| ROCE(%) | 32.85 |
| Trade Value ( ₹ in Lacs) | 300.43 |
|---|---|
| Market Cap (₹ in Mn) | 0.02 |
| Dividend Yield(%) | 0.54 |
| Price/Earning (TTM) | 11.68 |
| TTM EPS (₹) | 79.20 |
| P/E Ratio | 7.57 |
| Book Value(₹) | 1.80 |
| PAT Margin (%) | 39.54 |
| Face Value (₹) | 2.00 |
| ROCE(%) | 32.85 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 44295.0 | 12210.0 |
| Expenses | N/A | N/A |
| PBT | 22914.0 | 5059.0 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 18834.0 | 4060.0 |
About Natco Pharma Ltd.
| Founded | 1981 |
|---|---|
| Managing Director | V C Nannapaneni |
| NSE Symbol | NATCOPHARM |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,74,396.51 | 1,977.20 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,96,989.63 | 7,437.65 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,86,353.62 | 4,895.00 | 3,480.60 - 3,480.60 |
| Apollo Hospitals Enterprise Ltd. | 1,28,055.33 | 8,939.00 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,16,705.37 | 1,444.65 | 1,165.70 - 1,165.70 |
| Zydus Lifesciences Ltd. | 1,09,685.52 | 1,101.65 | 835.50 - 835.50 |
| Lupin Ltd. | 1,09,494.04 | 2,398.45 | 1,836.80 - 1,836.80 |
| Mankind Pharma Ltd. | 1,08,128.54 | 2,628.00 | 1,909.70 - 1,909.70 |
| Max Healthcare Institute Ltd. | 1,07,532.12 | 1,104.85 | 903.00 - 903.00 |
| Lenskart Solutions Ltd. | 96,299.04 | 556.00 | 0.00 - 0.00 |
No Records Found
Latest News
Natco Pharma informs about press release
NATCO Pharma informs about disclosure
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, NATCO Pharma has informed that it enclosed the disclosure as per format provided in SEBI Master Circular dated 30th January 2026.
Natco Pharma informs about press release
Zenotech Laboratories informs about outcome of board meeting
Further to the communication dated July 13, 2026, pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’) Zenotech Laboratories has informed that the Meeting of the Board of Directors of the Company was held today, July 28, 2026, which commenced at 11:30 AM and concluded at 2:30 PM, IST. The Board has, 1. Approved Unaudited Standalone Financial Results - The Unaudited Standalone Financial Results for the quarter ended June 30, 2026, as approved pursuant to Regulation 33 of the Listing Regulations, along with the Limited Review Report of the Statutory Auditors, are annexed herewith as Annexure A. 2. Approved convening 37th Annual General Meeting - The 37th Annual General Meeting (‘AGM’) of the Company will be held on Friday, September 25, 2026, at 10:30 AM IST through Videoconferencing. The Notice of the AGM and the Annual Report will be released in due course. Shareholders are requested to get their information updated with the depositories (for shares held in demat) or with the Company’s RTA (for shares held in physical form), so that Notice of the AGM and the Annual Report can be received by email.
The above information is a part of company’s filings submitted to BSE.
Indoco Remedies informs about change in management
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Natco Pharma Ltd. is ₹925.05 as of 2026-07-28.
The market capitalisation of Natco Pharma Ltd. is ₹16,561.39 as of 2026-07-28.
The 1-year return of Natco Pharma Ltd. is -16.20% as of 2026-07-28.
The P/E ratio of Natco Pharma Ltd. is 7.57 as of 2026-07-29.
The 52-week high and low of Natco Pharma Ltd. are ₹1,226.80 and ₹789.00, respectively, as of 2026-07-28.
People Also Ask
Natco develops generic and specialty drugs, with strong positions in oncology, cardiology, gastro, and CNS, plus agro‑chemicals through its crop‑health division.
Natco collaborates on licensing, contract manufacturing, and supplies hospital‑focused oncology generics and complex formulations in India and export markets.
Natco Pharma is an Indian pharmaceutical company that researches, develops, manufactures, and markets generic medicines, oncology‑focused products, active pharmaceutical ingredients (APIs), and agro‑health solutions for domestic and international markets.
NATCO is the brand and corporate name used by Natco Pharma Limited. The company does not prominently use or disclose an official expanded form of the abbreviation in its public corporate identity.
Before it became Natco Pharma Limited, the company was initially known as Natco Fine Pharmaceuticals, under which it started its operations in thepharmaceutical sector.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
